CVR number 33256965
Industry 75.0000 Veterinary activities

TUNE DYREKLINIK ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  5.7% 4.2% 3.2% 7.7% 6.0%  
Credit score (0-100)  40 47 56 30 39  
Credit rating  BBB BBB BBB BB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Gross profit  4,666 4,466 4,989 4,508 4,968  
EBITDA  861 812 1,147 227 422  
EBIT  643 513 844 -68.2 164  
Pre-tax profit (PTP)  612.8 530.5 878.7 -92.7 157.2  
Net earnings  474.4 410.0 686.6 -82.9 100.3  
Pre-tax profit without non-rec. items  613 531 879 -92.7 157  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Tangible assets total  1,104 1,460 1,200 1,338 1,112  
Shareholders equity total  859 1,119 1,656 1,373 1,323  
Interest-bearing liabilities  433 519 553 674 502  
Balance sheet total (assets)  2,932 3,279 3,271 3,137 3,044  
Net Debt  220 509 546 649 489  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  4,666 4,466 4,989 4,508 4,968  
Gross profit growth  28.9% -4.3% 11.7% -9.6% 10.2%  
Employees  8 8 7 8 7  
Employee growth %  0.0% 0.0% -12.5% 14.3% -12.5%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  2,932 3,279 3,271 3,137 3,044  
Balance sheet change%  32.5% 11.8% -0.2% -4.1% -3.0%  
Added value  861.2 811.7 1,147.1 234.9 422.4  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  54 57 -563 -158 -485  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  5.0 5.0 5.0 -1.0 1.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  13.8% 11.5% 16.9% -1.5% 3.3%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  25.0% 17.9% 27.5% -0.7% 6.6%  
ROI %  50.7% 35.3% 44.8% -1.0% 10.3%  
ROE %  76.3% 41.4% 49.5% -5.5% 7.4%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Equity ratio %  29.3% 34.1% 50.6% 43.8% 43.5%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  25.6% 62.8% 47.6% 285.9% 115.8%  
Gearing %  50.3% 46.4% 33.4% 49.1% 37.9%  
Net interest  0 0 0 0 0  
Financing costs %  5.9% 5.2% 4.0% 11.5% 8.2%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Quick Ratio  0.6 0.6 0.9 0.7 0.8  
Current Ratio  0.8 0.7 1.2 0.9 1.0  
Cash and cash equivalent  212.4 9.8 7.2 24.9 12.9  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -390.7 -535.1 269.5 -163.1 -12.8  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/12
Net sales / employee  0 0 0 0 0  
Added value / employee  108 101 164 29 60  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  108 101 164 28 60  
EBIT / employee  80 64 121 -9 23  
Net earnings / employee  59 51 98 -10 14